Navigation Links
Scripps Florida scientists awarded $1.5M to fight major water and food parasites
Date:10/28/2008

This award includes $1.5 million granted to the laboratory of William Roush, Ph.D., of Scripps Florida, a division of The Scripps Research Institute. Other participants in the consortium are University of California, San Diego (UCSD), University of California, San Francisco (UCSF), and University of Washington.

Roush, executive director of the Scripps Florida Translational Research Institute Medical Chemistry division and professor in the Scripps Research Department of Chemistry, is a co-principal investigator for the project.

"Amebiasis and giardia are serious diseases that affect thousands of people in the United States and throughout the world," Roush said. "Our work, along with others in the consortium, is to develop new small molecule inhibitors that will target specific proteases that play a critical role in the lifecycle of these parasites and bring these agents to the pre-clinical development stage."

It has been estimated that up to 10 percent of the world's population is infected with Entamoeba histolytica, the one-celled parasite that causes amoebiasis. The parasite Giardia lamblia is the most common cause of water-borne protozoal infection in the United States, with more than 20,000 cases each year.

Various laboratory studies have noted that both parasites have developed resistance to antibiotic treatment, setting off alarm bells within the health care community.

"Because of the rise in parasitic resistance, the development of more effective treatments has become even more critical, especially if we want to prevent future outbreaks," Roush said. "This funding helps bring together the expertise of four major laboratories that will focus on finding a solution to this serious threat to human health.

Attractive Targets

Roush's laboratory is looking at cysteine proteases, which are common in protozoan parasites and are involved in nutrition and immune system evasion. What makes these proteases attractive as therapeutic targets is that they are found in a number of different parasites, and that synthetic inhibitor libraries have already been developed against this enzyme family.

As a result, a wealth of inhibitor leads already exist, many of which have been subject to extensive pharmacokinetic and safety studies; for example cysteine protease inhibitors have already demonstrated potent anti-trypanosomal effects.

"This family of enzymes is well known biochemically and structurally," Roush said, "and we understand the relationship between structure and function that involves active site specificity. Our laboratory has used this information to help design new inhibitors that attack targets critical to invasive Entamoeba histolytica."

The new inhibitor designed by Roush's laboratory attacks the EhCP1 (Entamoeba histolytica cysteine proteinase), which is believed to be a virulence factor of this parasite.

"We have designed a compound that has very good properties as an inhibitor of this particular protease," Roush said. "When you kill this enzyme, you kill the parasite's ability to infect human tissue. In animal models, this molecule behaves beautifully in that capacity. Unfortunately, it's not an orally bioavailable compound, so right now we're working to optimize it to make it orally available."


'/>"/>

Contact: Keith McKeown
kmckeown@scripps.edu
858-784-8134
Scripps Research Institute
Source:Eurekalert

Related biology news :

1. Scripps research team sheds light on immune system suppression
2. Scripps research team solves structure of beneficial virus
3. Oceans on the precipice: Scripps scientist warns of mass extinctions and rise of slime
4. Scripps scientists will assess Beijing Olympics air pollution control efforts
5. Scripps study sets high economic value on threatened Mexican mangroves
6. Scripps research scientists reveal key structure from ebola virus
7. Scripps Research Institute awarded patent for remarkable chemical technology
8. Scripps Oceanography Research pegs ID of red tide killer
9. Fishing throws targeted species off balance, Scripps study shows
10. Bright lights: Mystery of glowing antibody solved by Scripps research scientists
11. Scripps expedition provides new baseline for coral reef conservation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... ... 2016 , ... Charm Sciences, Inc. is pleased to announce ... Research Institute approval 061601. , “This is another AOAC-RI approval of the Peel ... President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably to ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, the Industry Network for ... Design Lab . Located in Pasadena, Calif., the Design Lab’s mission is to ... are designed, built and brought to market. , The Design Lab is Supplyframe’s ...
(Date:6/23/2016)... , June 23, 2016  Blueprint Bio, a company ... to the medical community, has closed its Series A ... Nunez . "We have received a commitment ... capital we need to meet our current goals," stated ... us the runway to complete validation on the current ...
Breaking Biology Technology: